CompletedPHASE1, PHASE2NCT00470977
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
Studying Coats disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Principal Investigator
- Lawrence A. Yannuzzi, MD, M.DLuEsther T. Mertz Retinal Research Center
- Intervention
- ranibizumab injection (0.5 mg)(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2010
Study locations (2)
- Lenox Hill Hospital/Manhattan Eye Ear and Throat Institute, New York, New York, United States
- Lenox Hill Hospital/Manhattan Eye, Ear & Throat Institute, New York, New York, United States
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00470977 on ClinicalTrials.govOther trials for Coats disease
Additional recruiting or active studies for the same condition.